Innovent; 1st patient Dosed in a Phase III Clinical Trial of AntiPD1 Antibody Tyvyt as 1L Treatment for Advanced Esophageal Cancer $LLY httpswww.prnewswire.comnewsreleasesinnoventannouncesfirstpatientdosedinaphaseiiiclinicaltrialofa

Innovent; 1st patient Dosed in a Phase III Clinical Trial of Anti-PD-1 Antibody Tyvyt® as 1L Treatment for Advanced Esophageal Cancer $LLY https://www.prnewswire.com/news-releases/innovent-announces-first-patient-dosed-in-a-phase-iii-clinical-trial-of-a

05:08 EST 2 Jan 2019 | Odi Bruckman

Innovent; 1st patient Dosed in a Phase III Clinical Trial of Anti-PD-1 Antibody Tyvyt® as 1L Treatment for Advanced Esophageal Cancer $LLY https://www.prnewswire.com/news-releases/innovent-announces-first-patient-dosed-in-a-phase-iii-clinical-trial-of-anti-pd-1-antibody-tyvyt-sintilimab-injection-as-first-line-treatment-for-patients-with-advanced-esophageal-cancer-300771388.html …

More From BioPortfolio on "Innovent; 1st patient Dosed in a Phase III Clinical Trial of Anti-PD-1 Antibody Tyvyt® as 1L Treatment for Advanced Esophageal Cancer $LLY https://www.prnewswire.com/news-releases/innovent-announces-first-patient-dosed-in-a-phase-iii-clinical-trial-of-a"